There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Darbepoetin‐alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial
We conducted a r and omized study analyzing the impact of darbepoetin alfa ( DA ) administration with or without intravenous ( i.v . ) iron on erythroid recovery after autologous hematopoietic cell transplantation ( HCT ) . Patients were r and omized between no DA ( Arm 1 ) , DA 300 μg every 2 weeks starting on Day 28 after HCT ( Arm 2 ) , or DA plus i.v . iron 200 mg on Days 28 , 42 , and 56 ( Arm 3 ) . The proportion achieving complete hemoglobin ( Hb ) response within 18 weeks ( primary end point ) was 21 % in Arm 1 ( n = 24 ) , 79 % in Arm 2 ( n = 25 ) , and 100 % in Arm 3 ( n = 23 ; P < 0.0001 ) . Erythropoietic response was shown to be significantly higher in Arm 3 ( n = 46 ) than in Arm 2 ( n = 50 ; P = 0.008 ) , result ing in lower DA use , reduced drug costs , and improved quality of life scores , but the effect on transfusions was not significant . In multivariate analysis , DA administration ( P < 0.0001 ) , i.v . iron administration ( P = 0.0010 ) , high baseline Hb ( P < 0.0001 ) , and low baseline creatinine ( P = 0.0458 ) were independently associated with faster achievement of complete Hb response . In conclusion , DA is highly effective to ensure full erythroid reconstitution after autologous HCT when started on Day 28 post‐transplant . I.v . iron sucrose further improves erythroid recovery . Am . J. Hematol . 88:990–996 , 2013 . © 2013 Wiley Periodicals ,
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .